Specnuezhenide suppresses diabetes-induced bone loss by inhibiting RANKL-induced osteoclastogenesis

Specnuezhenide suppresses diabetes-induced bone loss by inhibiting RANKL-induced osteoclastogenesis

Diabetes osteoporosis is a chronic complication of diabetes mellitus (DM) and is associated with osteoclast formation and enhanced bone resorption. Specnuezhenide (SPN) is an active compound with anti-inflammatory and immunomodulatory properties. However, the roles of SPN in diabetic osteoporosis re...

Full description

Bibliographic Details
Main Authors: Ye Xiaoshuang, Jiang Juanjuan, Yang Juan, Yan Wenyan, Jiang Luyue, Chen Yan
Format: Article
Language:English
Published: China Science Publishing & Media Ltd. 2022-08-01
Series:Acta Biochimica et Biophysica Sinica
Subjects:
specnuezhenide
osteoclastogenesis
bone loss
RANKL
NF-κB
MAPK
Online Access:https://www.sciengine.com/doi/10.3724/abbs.2022094

Internet

https://www.sciengine.com/doi/10.3724/abbs.2022094

Similar Items